Ed Rosenthal and the Origins of High Times

Filed Under: Counterculture Architects

When I sat down with Ed Rosenthal, he did not arrive carrying nostalgia. He arrived with impatience for it.

A pipe in his hand, measured in tone, but direct from the start, he has little interest in the way cannabis history gets polished into something cleaner than it was.

High Times was founded in 1974. Over time, it picked up one of the most persistent origin myths in cannabis culture, that Tom Forçade dreamed it into existence in an acid-fueled flash of inspiration.

Rosenthal does not entertain it.

“That’s a really nice story, but it has nothing to do with reality.”

What he describes instead is not a moment. It is a process.

“I like to put things into numbers, and then from there you can reason out from that.”

The idea for the magazine did not come from a vision. It came from data, publishing experience, and a realization that the federal government had badly misjudged the size of the cannabis audience.

The first signal came from something mundane.

Rolling papers.

At the time, nearly all rolling papers used for joints were imported from Europe, including Zig Zag from France and multiple Spanish brands. American cigarette papers were not commonly used for cannabis, and imported papers were not widely used for tobacco.

“So if you look at the sales of rolling papers, it would correlate with sales of marijuana.”

The numbers told a story no one in government was willing to say out loud.

“Beginning in 1961 or 62, there was this uptick. Almost a vertical line going up.”

Rolling paper imports surged throughout the early 1960s, which Rosenthal viewed as an indicator that cannabis use was rising just as quickly.

Rosenthal recalls meeting with a researcher he identifies as Peter Canock, whom he believes was affiliated with the University of Florida.

From there, Rosenthal, Tom Forçade, and Ron Lichty began building a model.

“What was the weight of the average joint?”

“These were all guesstimates by the three of us.”

“But you know what? These were the best guesstimates in the United States.”

They worked through variables. Joint size. Frequency of use. The percentage consumed in pipes instead of paper.

Individually, the numbers were rough. Together, they pointed to something much larger.

“We came up with a figure of how many people were using cannabis at that time, and it was far, far higher than the DEA estimate.”

This analysis took place in 1972 and 1973, before the magazine launched.

Once that number was understood, the rest followed.

There was an audience. A large one. Large enough to support a publication.

The magazine was not a leap. It was a calculation.

At the time, all three were already working inside the underground press network. Publications like The East Village Other and the Los Angeles Free Press formed a loose national ecosystem. They understood publishing, distribution, and audience behavior.

They built a mock-up.

A list of roughly one hundred article ideas followed, enough to sustain the magazine well beyond a first issue. Many of those ideas would later appear in print.

Then they tested it.

The National Fashion and Boutique Show at the Hotel McAlpin in New York served as the closest thing to a trade show for the counterculture economy.

Rosenthal and his collaborators arrived with their mock-up and a pitch.

The response was immediate.

“We were deluged. It was unbelievable. We knew we had a hit.”

In Rosenthal’s telling, the origin was not an accident. It was market recognition.

The structure did not hold.

Rosenthal describes Forçade as someone who could be influenced by people he characterizes as questionable. Rosenthal believes at least one of those individuals may have had government connections, though he is clear he cannot prove it.

What he does remember is the break.

“Somebody riled him up about me. And he threw a fit and threw me out of the collective.”

Forçade took control. The original collaboration fractured before the magazine fully took shape.

Rosenthal’s relationship with High Times continued in different forms over the years. His writing and cultivation work remained part of the magazine’s identity until it ended.

“My last time I wrote for them was March of 2000.”

His reputation, however, was not built in publishing offices. It was built in conflict with the law.

In 2002, Rosenthal was deputized by the City of Oakland to cultivate cannabis under California’s medical marijuana program. Federal prosecutors intervened anyway.

He was convicted.

After the trial, jurors publicly stated they had not been informed that Rosenthal had been acting under city authorization.

His conviction was later vacated.

Federal law would override local reform whenever it chose to.

Rosenthal’s view of High Times itself is less romantic than its reputation.

“It was geared to two groups. Hippies, and a more intellectual group of people who smoked pot.”

That combination defined its voice.

“It had really serious essays. Serious writers. Serious research that it did.”

That audience, in his view, no longer exists in the same way.

“There’s a different culture now than there was then.”

Cannabis has moved into the mainstream. The conditions that once justified a specialized magazine have changed.

“Cannabis has permeated the culture so much that you don’t necessarily need a specialized magazine for it.”

The question, as he frames it, is simple.

“What niche is that magazine going to hold?”

Before publishing, Rosenthal was already operating inside the movement itself.

“I was in the Yippies. At one point, we were literally the only organization doing anything.”

Their methods were not symbolic.

“Mocking and disruptive. That’s also a description of my personality.”

Public smoke-ins became one of their most effective tools. Not just a protest, but a demonstration.

Participants looked around and realized something they had not been told.

They were not alone.

“They had to look around and found out that they weren’t the only ones. That they were the majority.”

Those gatherings created momentum.

“We left little cancers wherever those Smokins took place. And that is effectively what created the marijuana movement.”

Later, his work took him outside the United States.

“In 1981, I was traveling through India, and I saw this gigantic marijuana field.”

The field was located near Khandwa in the Indian state of Madhya Pradesh and was legally producing cannabis for retail sale at the time.

Rosenthal obtained permission from Bhopal officials and documented it.

Decades later, the significance became clear.

“If I hadn’t photographed it, that entire knowledge would have been lost.”

The plants were regional landrace strains, part of a system that no longer exists in the same form.

Markets shift. Laws change. Narratives harden into myth.

Rosenthal’s version of the origin of High Times does not rely on myth at all. It rests on numbers, observation, and a simple conclusion.

The audience was already there.

Someone just had to recognize it.

What came next was something else entirely.

Ed Rosenthal’s work didn’t stop with High Times. He continues to advocate for cannabis reform globally, including efforts to re-legalize cannabis in India and preserve native landrace strains that are increasingly threatened by commercialization and eradication policies.

Through his ongoing writing, research, and public work, Rosenthal remains one of the most active voices connecting cannabis culture, policy, and cultivation.

Readers can explore more of his work, including books, articles, and current projects, at EdRosenthal.com.

F O R T H E C U L T U R E B Y T H E C U L T U R E

Ed Rosenthal and the Origins of High Times

Ed Rosenthal recounts how the magazine was born not from psychedelic myth but from hard numbers. Rolling paper import data, underground press experience, and market logic revealed a massive hidden cannabis audience. His account challenges the romantic origin story and offers a rare firsthand look at the early mechanics behind one of cannabis culture’s most…

Ohio’s Hemp Ban Hits a Wall in Court

Ohio’s attempt to restrict intoxicating hemp sales is already facing legal resistance. A judge has blocked enforcement of key provisions, raising questions about whether the law protects consumers or reshapes the cannabis market. The case could set a precedent for how states regulate hemp derived THC products across the country.

CANNABIS LIES Vol. 8: The Addiction Lie

Cannabis is often labeled addictive, but the science tells a more precise story. This piece breaks down cannabis use disorder, how it is defined, and why mild, moderate, and severe cases get flattened into one fear-driven narrative. The result is a distorted public understanding of risk that fuels policy, perception, and misinformation.

CANNABIS LIES Vol. 8: The Addiction Lie

Filed Under: Manufactured Dependence

They don’t argue the old myths the same way anymore. The language has changed. The tone sounds calmer, more clinical, and harder to push back on without looking reckless. Nobody is yelling that cannabis turns people into criminals or ruins their moral character. That version burned out. What replaced it sounds smarter. Now the claim comes dressed as a public health concern. Cannabis is addictive. Cannabis is a disorder. Cannabis is quietly pulling people in.

That shift matters, because the word doing all the work is not weed. It is an addiction.

The term lands heavily. It carries the weight of opioids, alcohol, and nicotine, the substances that grip people, wreck bodies, tear through families, and leave a trail that is impossible to ignore. When cannabis gets pulled into that same word, the comparison happens automatically. The public does not stop to sort through definitions or diagnostic criteria. They hear addiction and picture collapse.

The science is not saying it that broadly.

What it actually says is narrower, more conditional, and a lot less dramatic. Cannabis can lead to a diagnosable condition called cannabis use disorder. That part is real. It is defined in clinical terms, measured against a checklist, and recognized by institutions that track substance use and mental health. It exists. Ignoring it would be dishonest.

But the way it is framed outside those clinical boundaries is where the distortion begins.

Cannabis use disorder is not a single state. It is a spectrum. The diagnostic model used in the DSM-5-TR identifies eleven criteria, ranging from increased tolerance to difficulty cutting back to continued use despite problems. Meeting two of those criteria qualifies as a mild case, four to five moves it into moderate, and six or more lands in severe territory. That range matters because it means a person can meet the definition of a disorder without fitting the public image of addiction at all.

This is not a technical footnote. It is the whole game.

Once the label gets applied, the distinctions inside it disappear in public conversation. Mild cases, moderate cases, and severe cases all get flattened into one word. Addiction. The spectrum collapses into a headline. A diagnosis that was built to capture nuance gets repackaged as a blunt instrument.

That is where the narrative drifts away from the evidence.

The most commonly cited numbers follow the same pattern. The Centers for Disease Control and Prevention states, “About 3 in 10 people who use cannabis have cannabis use disorder.” The National Institute on Drug Abuse has long reported that about nine percent of users develop dependence, with higher numbers among current users and those who start young. Both statements are accurate within different definitions and populations. Neither one means what the average reader thinks it means when the word addiction gets attached.

Those numbers do not describe a population collapsing into severe, compulsive drug use. They are describing a range of behaviors, from mild patterns that meet minimal criteria to more serious cases that require intervention. The distinction is buried as soon as the statistic leaves its original context. Thirty percent sounds like a crisis. Nine percent sounds manageable. Both can be used to push a narrative depending on how they are framed.

That elasticity is not accidental.

MORE CANNABIS LIES

CANNABIS LIES Vol. 7: The Mental Health Panic

Cannabis and mental health risks are often overstated in public debate. Research shows heavy use and high THC exposure can increase psychosis risk in vulnerable individuals, but widespread claims of a mental health crisis lack strong evidence. This piece examines the data, separates correlation from causation, and breaks down what cannabis users need to know.

CANNABIS LIES Vol. 6: The Driving Apocalypse Lie

Legal cannabis is often blamed for rising traffic deaths, but federal data tells a more complicated story. NHTSA findings, toxicology limitations, and conflicting crash studies reveal that THC presence is not a reliable measure of impairment. This investigation breaks down how flawed testing and policy shortcuts have shaped the narrative around so-called stoned driving.

CANNABIS LIES Vol. 5: The Gateway Lie

For decades, politicians have claimed marijuana is a gateway to heroin and harder drugs. Federal youth surveys, NSDUH data, and NIDA’s own language tell a different story. Cannabis use is widespread, hard drug use remains rare, and most users do not progress. The data dismantles one of prohibition’s most durable fear narratives.

Risk increases under specific conditions. Starting young raises it. Using it frequently raises it. High THC exposure raises it. Those patterns show up consistently across research, and ignoring them would be as misleading as exaggerating them. The CDC states plainly that the risk of developing cannabis use disorder is greater in people who begin during adolescence and use more often. That is a targeted warning, not a universal one.

The broader claim, that cannabis functions as a widely addictive substance in the same category as alcohol or opioids, does not hold under the same scrutiny.

Withdrawal is where the difference becomes harder to ignore. People who use cannabis heavily can experience symptoms when they stop. Irritability, sleep disruption, appetite changes, restlessness. Those symptoms are real, documented, and worth acknowledging. They are also generally mild and not life-threatening. That stands in sharp contrast to substances like alcohol, where withdrawal can be medically dangerous, or opioids, where the physical severity can be extreme.

That gap is not a minor detail. It defines the category.

Severe physical dependence, in the way the public often understands addiction, involves a level of physiological reliance that creates severe, often dangerous withdrawal and powerful compulsive use. Cannabis does not fit that profile. It can create habits. It can create dependence in some users. It can become part of a pattern that is difficult to break. But it does not produce the same physical cascade that drives the most destructive forms of addiction.

The problem is that the language used to describe it does not always respect that difference.

In clinical settings, cannabis use disorder is treated as a spectrum condition. In public discourse, it often gets presented as a binary. Either you are fine, or you are addicted. That simplification makes the story easier to tell, but it strips out the very nuance the diagnosis was designed to capture. It also opens the door for the term addiction to do work it was never meant to do in this context.

Once that word is in play, the comparison does the rest.

A narrow concern is being sold as a sweeping emergency. Public warnings turn a concentrated risk into a general threat.

This is where media framing and policy language start to overlap. Headlines lean toward the most alarming interpretation. Reports highlight the highest percentage. Statements get shortened until only the most striking part survives. A clinical description of a range of outcomes becomes a cultural warning about a single, escalating threat. The distance between the original research and the final message widens with each step.

One study becomes a headline. One headline becomes a talking point. One talking point becomes policy.

None of this requires a conspiracy. It runs on incentives that reward clarity over accuracy and impact over precision.

That does not mean the underlying concern should be dismissed. Some people struggle with cannabis use. There are cases where use becomes compulsive, disruptive, and difficult to control. Younger users are more vulnerable to negative outcomes. Those realities deserve to be addressed without minimizing them or turning them into something they are not.

Cannabis can be misused. The real issue is how that misuse gets defined, measured, and communicated.

When a spectrum condition is presented as a single outcome, the public loses the ability to understand where the real risk sits. When dependence, habit, and heavy use are grouped under one label, the label becomes less useful and more political. It stops describing behavior and starts shaping perception.

That shift has consequences.

Policy decisions, workplace rules, and public attitudes all respond to the language used to describe risk. If cannabis is framed as broadly addictive, it becomes easier to justify stricter controls, harsher penalties, and continued suspicion around its use. If the nuance is preserved, the conversation changes. Risk becomes something to manage rather than something to fear indiscriminately.

That is the line this argument sits on.

Cannabis use disorder is real. It exists on a spectrum. It affects a subset of users, more heavily under certain conditions, and more seriously in its severe forms. Those are the facts. What does not follow from those facts is the idea that cannabis operates as a broadly addictive substance in the same class as the drugs that have historically defined that word.

The gap between those two ideas is where the lie lives.

It is not a lie built on fabrication. It is built on compression. Take a layered diagnosis, flatten it into a single term, remove the gradations, and present the result as a general truth. The details do not disappear completely. They just stop being the part people remember.

Once that happens, the word addiction does not describe the reality anymore. It replaces it.

©2026 Pot Culture Magazine. All rights reserved. This content is the exclusive property of Pot Culture Magazine. It may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission from the publisher, except for brief quotations in critical reviews.

F O R T H E C U L T U R E B Y T H E C U L T U R E

Australia Cracks Down on Medical Cannabis

Australia’s medical cannabis system expanded rapidly through telehealth and high-volume prescribing. Now regulators are tightening oversight. The TGA and AHPRA are increasing scrutiny on prescribing practices, signaling a shift from rapid patient access toward stricter clinical control that could reshape how doctors prescribe and how patients obtain treatment.

Missouri Tightens Grip On Hemp Sales

Missouri legalized cannabis, then moved to squeeze intoxicating hemp into the dispensary system. HB 2641 is being sold as consumer protection, but critics say it protects licensed marijuana operators while threatening hemp retailers, growers, and small businesses across the state.

IDAHO TRIES TO STOP A VOTE BEFORE IT STARTS

Idaho lawmakers passed a resolution urging voters to reject a medical cannabis initiative before it reaches the ballot. The move highlights how officials are shaping public opinion ahead of a vote, while maintaining strict prohibition and blocking even limited access for patients.

Australia Cracks Down on Medical Cannabis

Filed Under: Access Expanded, Control Returns

Australia did not ease into medical cannabis. It accelerated fast.

A tightly controlled, case-by-case framework turned into one of the fastest-growing prescription markets in the world. Telehealth clinics scaled access, prescribing volumes climbed, and patients who once faced long delays found pathways that moved in days instead of months.

Growth followed, and regulators took notice.

Pressure is no longer subtle.

The system is still legal. Access has not been shut down. What changed is how closely it is being watched, and how quickly that scrutiny is turning into action.

At the center of that shift sits the Therapeutic Goods Administration (TGA), the federal regulator responsible for overseeing therapeutic goods, including medical cannabis. The TGA does not legalize cannabis in the recreational sense. It governs how unapproved therapeutic products move through a tightly controlled framework.

Most medical cannabis in Australia exists under the Special Access Scheme (SAS) and the Authorised Prescriber Scheme (APS). These pathways allow doctors to prescribe products that are not formally registered on the Australian Register of Therapeutic Goods (ARTG).

The structure opened the door and allowed scale to follow.

Approvals have reached the hundreds of thousands, according to published TGA data, reflecting how quickly patients entered the system once access barriers dropped. Chronic pain, anxiety, and sleep disorders became common entry points, often after conventional treatments failed or produced unwanted side effects.

Telehealth changed the pace.

Doctors could assess patients remotely. Prescriptions could be issued without in-person visits. Clinics began operating nationally without the limits of physical locations. Access became faster, quieter, and easier to navigate for patients who had previously stayed out of the system.

Those same conditions are now under scrutiny.

By 2024, the TGA publicly signaled that it was monitoring prescribing patterns more closely, especially where prescribing volumes appeared inconsistent with expected clinical practice. That scrutiny carried into 2026 and shifted direction. Observation is giving way to compliance activity and targeted enforcement.

Recent TGA communications and guidance updates emphasize concerns about high-volume prescribing, repeat authorizations, and models that rely heavily on telehealth as the primary entry point into treatment. The language stays clinical. The message does not.

Regulators are drawing a line between individualized care and large-scale prescribing models.

Medical cannabis remains an unapproved therapeutic category under Australian law. Prescribing it requires clinical justification that can withstand review. That standard has always existed. Now it is being applied with more weight behind it.

The Australian Health Practitioner Regulation Agency (AHPRA) has also stepped in, not as a cannabis specific regulator, but through its standard oversight of prescribing practices. AHPRA focuses on professional conduct, ensuring that doctors meet expected standards regardless of the treatment involved.

When scrutiny moves from product oversight into practitioner conduct, the pressure changes.

Doctors are being reminded that prescribing cannabis requires the same level of clinical assessment as any other controlled therapeutic. Patient history, documentation, and justification must hold up under examination. High prescribing volumes without clear reasoning are being flagged as compliance risks.

Telehealth sits right in the middle of this.

MORE FROM POT CULTURE MAGAZINE

Thailand Lost Control

Thailand blew open its cannabis market, then tried to force it back under control. This feature tracks the country’s shift from prohibition to medical legalization, decriminalization, and regulatory backlash, exposing how weak enforcement, political pressure, and rushed policy turned a reform headline into a live case study in state correction.

South Africa Legalized Weed, But Not the Market

South Africa recognized private adult cannabis use and home cultivation, but never built a legal domestic market around them. With buying and selling still largely outside the law, the illicit trade remains dominant while regulators scramble to set limits, draft rules, and prepare a broader Cannabis Bill that could finally address commerce.

Remote access made the system work at scale. It also created distance between consultation and verification. Regulators are now looking harder at how those consultations are conducted, how conditions are confirmed, and how prescribing decisions are made.

Telehealth is still allowed. The expectations around it are tightening.

The TGA has made clear that prescribing decisions must remain patient-specific and evidence-informed, whether the consultation happens in person or remotely. That raises the bar for clinics built around speed and volume.

Some providers are already adjusting.

Australian reporting points to clinics reviewing internal protocols, tightening intake requirements, and pulling back on prescribing volume to stay inside what they expect regulators will accept. Others are dealing with audits and compliance checks tied directly to prescribing patterns.

Patients are starting to feel it.

Appointments that once led to rapid prescriptions are taking longer. Some prescribers are more selective, asking for additional documentation or declining cases that would have moved forward without hesitation a year ago.

Access has not disappeared. It just no longer moves the same way.

Official data continues to reflect how quickly the system expanded. The TGA has processed a rapidly increasing number of approvals through the Special Access Scheme, reflecting sustained growth in patient participation. Telehealth played a measurable role by removing geographic and logistical barriers.

The response to that expansion is shaping what comes next.

Regulators are not arguing against access. They are reinforcing that access must hold up inside a clinical framework. That line is where the system lives or breaks.

Medical cannabis in Australia is not a consumer product moving through an open market. It exists inside a structure designed to control how unapproved therapies are prescribed and used. When prescribing starts to look like distribution, oversight tightens.

That shift is already happening.

The legal framework remains intact. Doctors can still prescribe. Patients can still obtain treatment. The conditions around those decisions are becoming more restrictive, more documented, and more closely watched.

This is not random.

Australia’s model expanded quickly because it allowed flexibility where other systems imposed rigid gatekeeping. That flexibility created access at scale, but it also introduced variation in how that access was delivered.

Some providers stayed within conservative clinical limits. Others built high-volume prescribing models that relied on telehealth efficiency and repeat authorizations to sustain growth.

Regulators are now responding to that gap.

The focus is not on cannabis itself. It is a prescribing behavior.

Framing it that way allows regulators to maintain the legitimacy of the medical system while targeting practices that fall outside expected clinical standards. It is narrow, and it carries real consequences.

Clinics are adjusting their models.

Doctors are working under closer scrutiny.

Patients are moving through a system that no longer prioritizes speed above everything else.

This pattern is not new.

Access expands. Demand follows. Infrastructure scales. Oversight catches up. What stands out here is the speed at which it all happened.

Telehealth accelerated access. Regulators are now accelerating control.

The outcome is still forming. The direction is already set.

Targeted enforcement could stabilize the system without cutting off access. Broader pressure could tighten eligibility, reduce prescribing options, and extend wait times for patients seeking treatment.

How hard regulators push will decide what survives.

The framework itself did not change overnight. The way it is being applied did.

Across the system, that shift carries weight.

Medical cannabis in Australia is no longer defined by how quickly patients can enter. It is being defined by how tightly that access is managed once they do.

This is not theoretical. It is already playing out across clinics, consultations, and prescriptions.

Regulators are not trying to erase the system.

They are trying to bring it back under control before they lose control of it.

©2026 Pot Culture Magazine. All rights reserved. This content is the exclusive property of Pot Culture Magazine. It may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission from the publisher, except for brief quotations in critical reviews.

F O R T H E C U L T U R E B Y T H E C U L T U R E

Ed Rosenthal and the Origins of High Times

Ed Rosenthal recounts how the magazine was born not from psychedelic myth but from hard numbers. Rolling paper import data, underground press experience, and market logic revealed a massive hidden cannabis audience. His account challenges the romantic origin story and offers a rare firsthand look at the early mechanics behind one of cannabis culture’s most…

Ohio’s Hemp Ban Hits a Wall in Court

Ohio’s attempt to restrict intoxicating hemp sales is already facing legal resistance. A judge has blocked enforcement of key provisions, raising questions about whether the law protects consumers or reshapes the cannabis market. The case could set a precedent for how states regulate hemp derived THC products across the country.

CANNABIS LIES Vol. 8: The Addiction Lie

Cannabis is often labeled addictive, but the science tells a more precise story. This piece breaks down cannabis use disorder, how it is defined, and why mild, moderate, and severe cases get flattened into one fear-driven narrative. The result is a distorted public understanding of risk that fuels policy, perception, and misinformation.

What’s everyone’s take on CBG Chronic? 🌿 If you’ve tried it, I’d love to hear your thoughts. Let's share our experiences!

#CBG #Cannabis #CBD #CBGChronic #Chronic #Health #Wellness #CannabisCommunity #NaturalRemedies #StrainReview #CBDOil #HealthBenefits #CBDLife #ChronicPain #HolisticHealth